Literature DB >> 22403059

Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Ho-Young Yhim, Hee Sun Kim, Na-Ri Lee, Eun-Kee Song, Jae-Yong Kwak, Chang-Yeol Yim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22403059     DOI： 10.1007/s12185-012-1045-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  12 in total

1.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

2.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

3.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Authors:  P Lindahl; B R Johansson; P Levéen; C Betsholtz
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

4.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

Authors:  Hagop Kantarjian; Ricardo Pasquini; Nelson Hamerschlak; Philippe Rousselot; Jerzy Holowiecki; Saengsuree Jootar; Tadeusz Robak; Nina Khoroshko; Tamas Masszi; Aleksander Skotnicki; Andrzej Hellmann; Andrey Zaritsky; Anatoly Golenkov; Jerald Radich; Timothy Hughes; Athena Countouriotis; Neil Shah
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

5.  Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Deborah Thomas; Gabriela Vidal-Senmache; William Wierda; Steven Kornblau; Jorge Cortes
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

6.  The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

Authors:  Marie-Pierre Gratacap; Valérie Martin; Marie-Cécile Valéra; Sophie Allart; Cédric Garcia; Pierre Sié; Christian Recher; Bernard Payrastre
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

7.  Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

Authors:  Oliver Ottmann; Hervé Dombret; Giovanni Martinelli; Bengt Simonsson; Francois Guilhot; Richard A Larson; Giovanna Rege-Cambrin; Jerald Radich; Andreas Hochhaus; Anne Marie Apanovitch; Ashwin Gollerkeri; Steven Coutre
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

8.  Metabolism and disposition of dasatinib after oral administration to humans.

Authors:  Lisa J Christopher; Donghui Cui; Chiyuan Wu; Roger Luo; James A Manning; Samuel J Bonacorsi; Michael Lago; Alban Allentoff; Francis Y F Lee; Betty McCann; Susan Galbraith; Donald P Reitberg; Kan He; Anthony Barros; Anne Blackwood-Chirchir; W Griffith Humphreys; Ramaswamy A Iyer
Journal:  Drug Metab Dispos       Date:  2008-04-17       Impact factor: 3.922

9.  Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.

Authors:  Michael Brave; Vicki Goodman; Edvardas Kaminskas; Ann Farrell; William Timmer; Sarah Pope; Ravi Harapanhalli; Haleh Saber; David Morse; Julie Bullock; Angela Men; Carol Noory; Roshni Ramchandani; Leslie Kenna; Brian Booth; Joga Gobburu; Xiaoping Jiang; Rajeshwari Sridhara; Robert Justice; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

10.  Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Xin Han; Hagop Kantarjian; Jorge Cortes
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113
View more
  1 in total

1.  Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports.

Authors:  Xin Liao; Yuxia Guo; Yali Shen; Jianwen Xiao
Journal:  Case Rep Hematol       Date:  2020-02-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.